Benefits of Semantic Enrichment Across the Drug Development Pipeline

whitePaper | November 24, 2022

The pharmaceutical industry will face many challenges over the next decade, from industry-wide trends to new operational pressures. The key to meeting these challenges is adopting an agile, scalable and efficient approach to drug discovery and manufacturing.

whitePaper | January 1, 2020

With over 2,800 campaigns each year delivered through a team of 300+ digital, data, and technology specialists, Deck 7 is a first resource for B2B demand generation services for marketers worldwide. Clients leverage Deck 7’s multichannel content marketing services and Media 7’s network of 30+ online publications for content syndication to engage over 95 million buyers across 16 industries and 120+ countries.

whitePaper | April 7, 2021

In less than a week, in the face of a pandemic, the pharmaceutical sales model changed forever. In-person healthcare provider (HCP) visits came to a screeching halt and brand marketers scrambled to find ways to educate and engage these providers remotely. While the pandemic may have taken us by surprise, we should acknowledge that, even before the pandemic, pharmaceutical sales teams faced significant challenges. One solution for these challenges is to engage HCPs – virtually.

whitePaper | February 24, 2022

The COVID-19 pandemic and resulting economic dislocation revealed long-standing vulnerabilities in our supply chains. The pandemic’s drastic impacts on demand patterns for a range of medical products including essential medicines wreaked havoc on the U.S. healthcare system.

whitePaper | August 8, 2021

If Pharma is to create a new marketing and sales model that is fit for 2020, it will have to begin by analysing its own value chain to identify opportunities for working more closely with healthcare payers and providers. It will, for example, have to collaborate much more closely with payers (be they governments, health insurers, employers or patients) to ensure that it develops medicines which have real social and economic value.

whitePaper | April 12, 2022

The level of pharmaceutical expenditure is closely watched and often commented upon, but the composition of that expenditure and its dynamics are not as well understood.